rdus highest level of sales estimates are pretty close to or maybe a little above a billion dollars

If we look ahead, we might see that analysts are bullish on the potential for abaloparatide, and the highest level of sales estimates are pretty close to or maybe a little above a billion dollars. Radius Health Inc (NASDAQ:RDUS) will have to do a lot before it can earn any revenue from this drug but today’s announcement is certainly a good sign for the company. Investors should keep in mind that Radius is still a high-risk company which is currently burning more than $60 million in operating cash per year as it works to develop abaloparatide.
Read more at http://www.insidermonkey.com/blog/radius-health-inc-rdus-up-on-positive-trial-data-should-you-buy-354747/2/#i0URYUg6tOQHIEOe.99